Back to listings
Compound & Molecule
Potent and Selective JAK1 Inhibitor for Atopic Dermatitis
PharmaSynth LabsListed Mar 9, 2026
Description
A highly selective JAK1 inhibitor (>100x selectivity over JAK2/JAK3/TYK2) developed for topical treatment of moderate-to-severe atopic dermatitis. Demonstrates dose-dependent reduction of TSLP and IgE in murine AD model. Clean off-target selectivity panel (>1000 kinases). Pharmaceutical-grade synthesis route established with 3 CMO relationships.
Tags
JAK1dermatologyatopic dermatitistopicalimmunology
Technical Details
- CAS Number
- 1834937-12-0
- Molecular Weight
- 412.49 g/mol
Asking Price
$4,200,000
About the Seller
Prof. James O'Brien
PharmaSynth Labs
Drug discovery expert specializing in oncology and rare diseases.